human
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: A r and omized trial was arranged in Yorkshire to assess whether progestogens would improve survival as part of the primary treatment of endometrial carcinoma , in conjunction with surgery and radiotherapy .  A total of 429 patients was r and omized on diagnosis to the progestogen or control group  and treated locally according to an agreed protocol . All the patients are now more than 1 year after operation and over half are more than 5 years after operation . The projected overall 5-year survival rate is 76 % but contrary to expectation there is no statistically significant difference in survival between the patients treated with progestogens and the control group even after statistical adjustment for known prognostic factors A multicentre trial on patients with apparent stage I endometrial carcinoma was conducted with the aims of defining a treatment plan on the basis of the pathological disease extension and of evaluating the effectiveness of adjuvant medroxyprogesterone acetate ( MPA ) . After surgery , patients with disease limited to the endometrium did not receive any further treatment . Patients with inner myometrial invasion and well or moderate differentiation were r and omised to no further treatment vs. MPA 100 mg orally twice a day for 12 months ; patients with moderate or deep myometrial invasion or undifferentiated grade were r and omised to radiotherapy on pelvis vs. radiotherapy plus MPA , and patients with node-positive disease ( N+ ) were su bmi tted to radiotherapy on pelvis and para-aortic nodes vs. radiotherapy plus MPA . At 84 months , analysis as intention to treat on 856 patients shows a high relapse-free survival , whereas it did not show any significant difference between the MPA-treated and untreated groups . The study indicates that relapse-free survival is influenced by a treatment based on the pathological extension of the disease and that adjuvant hormonotherapy does not improve the cure rate A r and omized , controlled trial was design ed to determine whether adjuvant progestagen therapy improves survival in patients with Stage I or Stage II endometrial cancer . After surgery , 1148 patients were r and omly assigned to adjuvant treatment with progesterone or were given no additional therapy . The duration of follow‐up ranged from 42 to 132 months ( median follow‐up , 72 months ) . Crude survival and relapse rates were similar for both groups . Death due to intercurrent disease was higher in the progesterone group ( P = 0.04 ) . The median survival of the group of patients with cancer‐related death was higher in the progestagen group than in the control group ( 30 and 22 months , respectively ; P = 0.03 ) . In 461 high‐risk patients , a tendency towards fewer cancer‐related deaths and a better disease‐free survival in the treatment group was observed , but crude survival was unchanged . We conclude that there is little to gain from adjuvant progestagen therapy in patients with low‐risk endometrial cancer , and that further studies are needed in high‐risk patients Abstract On the basis of reported successful hormone therapy for recurrent cancer of the endometrium , a multi-institutional program was established in 1963 and terminated in 1968 to study the adjuvant use of a progestogen in the primary definitive treatment of uterine carcinoma . The research protocol restricted entry to patients with disease limited to the uterine corpus as established by clinical evaluation , surgery , and pathology . Option of surgery alone or surgery plus irradiation was permitted . Depo-Provera and placebo given over 14 wk were r and omly assigned in such a way that 285 patients received hormone ; 287 served as controls .  Survival analysis at 4 yr indicated no significant contribution to results by the adjuvant therapy .  Overall excellent survival for treated patients and controls appeared to be the result of the high degree of patient selection incorporated in the protocol design . The influence of patient selection and of variations of disease-related parameters upon the results is discussed especially as it may affect future programs dealing with comparable patient material 
    Output:
    
agent
***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: A r and omized trial was arranged in Yorkshire to assess whether progestogens would improve survival as part of the primary treatment of endometrial carcinoma , in conjunction with surgery and radiotherapy .  A total of 429 patients was r and omized on diagnosis to the progestogen or control group  and treated locally according to an agreed protocol . All the patients are now more than 1 year after operation and over half are more than 5 years after operation . The projected overall 5-year survival rate is 76 % but contrary to expectation there is no statistically significant difference in survival between the patients treated with progestogens and the control group even after statistical adjustment for known prognostic factors A multicentre trial on patients with apparent stage I endometrial carcinoma was conducted with the aims of defining a treatment plan on the basis of the pathological disease extension and of evaluating the effectiveness of adjuvant medroxyprogesterone acetate ( MPA ) . After surgery , patients with disease limited to the endometrium did not receive any further treatment . Patients with inner myometrial invasion and well or moderate differentiation were r and omised to no further treatment vs. MPA 100 mg orally twice a day for 12 months ; patients with moderate or deep myometrial invasion or undifferentiated grade were r and omised to radiotherapy on pelvis vs. radiotherapy plus MPA , and patients with node-positive disease ( N+ ) were su bmi tted to radiotherapy on pelvis and para-aortic nodes vs. radiotherapy plus MPA . At 84 months , analysis as intention to treat on 856 patients shows a high relapse-free survival , whereas it did not show any significant difference between the MPA-treated and untreated groups . The study indicates that relapse-free survival is influenced by a treatment based on the pathological extension of the disease and that adjuvant hormonotherapy does not improve the cure rate A r and omized , controlled trial was design ed to determine whether adjuvant progestagen therapy improves survival in patients with Stage I or Stage II endometrial cancer . After surgery , 1148 patients were r and omly assigned to adjuvant treatment with progesterone or were given no additional therapy . The duration of follow‐up ranged from 42 to 132 months ( median follow‐up , 72 months ) . Crude survival and relapse rates were similar for both groups . Death due to intercurrent disease was higher in the progesterone group ( P = 0.04 ) . The median survival of the group of patients with cancer‐related death was higher in the progestagen group than in the control group ( 30 and 22 months , respectively ; P = 0.03 ) . In 461 high‐risk patients , a tendency towards fewer cancer‐related deaths and a better disease‐free survival in the treatment group was observed , but crude survival was unchanged . We conclude that there is little to gain from adjuvant progestagen therapy in patients with low‐risk endometrial cancer , and that further studies are needed in high‐risk patients Abstract On the basis of reported successful hormone therapy for recurrent cancer of the endometrium , a multi-institutional program was established in 1963 and terminated in 1968 to study the adjuvant use of a progestogen in the primary definitive treatment of uterine carcinoma . The research protocol restricted entry to patients with disease limited to the uterine corpus as established by clinical evaluation , surgery , and pathology . Option of surgery alone or surgery plus irradiation was permitted . Depo-Provera and placebo given over 14 wk were r and omly assigned in such a way that 285 patients received hormone ; 287 served as controls .  Survival analysis at 4 yr indicated no significant contribution to results by the adjuvant therapy .  Overall excellent survival for treated patients and controls appeared to be the result of the high degree of patient selection incorporated in the protocol design . The influence of patient selection and of variations of disease-related parameters upon the results is discussed especially as it may affect future programs dealing with comparable patient material 
    Output:
    